US · RCUS · BIOTECHNOLOGY
Arcus Biosciences, Inc. (RCUS) intrinsic value and stock valuation
$15.62as of 2026-11-21 · Mkt cap 3.6B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Arcus Biosciences, Inc. DCF and intrinsic value
InvestorsCraft values RCUS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RCUS’s statements →
Arcus Biosciences, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $247M | $258M | $117M | $112M | $383M |
| Operating income | -$-386M | -$-330M | -$-340M | -$-280M | $54M |
| Net income | -$-353M | -$-283M | -$-307M | -$-267M | $53M |
| EPSd | -$-3.29M | -$-3.14M | -$-4.15M | -$-3.71M | $716.5K |
| Operating cash flow | -$-482M | -$-170M | -$-306M | $438M | -$-256.17M |
| Capital expenditure | -$-2M | -$-6M | -$-24M | -$-6M | -$-26.08M |
| Free cash flow | -$-484M | -$-176M | -$-330M | $432M | -$-282.25M |
| Total assets | $1.14B | $1.15B | $1.1B | $1.35B | $1.59B |
| Total debt | $112M | $60M | $11M | $120M | $122M |
| Net debt | -$-110M | -$-90M | -$-116M | -$-86M | -$-25.93M |
| Total equity | $631M | $485M | $462M | $657M | $841.5M |
| Cash and short-term investments | $981M | $978M | $759M | $1.01B | $499.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $247M | $258M | $117M | $112M | $383M |
| Cost of revenue | $10M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $237M | $258M | $117M | $112M | $383M |
| Research and development expenses | $523M | $448M | $340M | $288M | $257M |
| Selling, general and administrative expenses | $110M | $120M | $117M | $104M | $72M |
| Other expenses | -$-10M | $20M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $623M | $588M | $457M | $392M | $329M |
| Cost and expenses | $633M | $588M | $457M | $392M | $329M |
| Interest income | $41M | $52M | $41M | $16M | $1M |
| Interest expense | $8M | $4M | $2M | $2M | $0.00 |
| Depreciation and amortization | $10M | $10M | $8M | $6M | $4M |
| Ebitda | -$-335M | -$-269M | -$-291M | -$-258M | $59M |
| Operating income | -$-386M | -$-330M | -$-340M | -$-280M | $54M |
| Total other income/expenses, net | $33M | $47M | $39M | $14M | $1M |
| Income before tax | -$-353M | -$-283M | -$-301M | -$-266M | $55M |
| Income tax expense | $0.00 | $1M | $6M | $1M | $2M |
| Net income | -$-353M | -$-283M | -$-307M | -$-267M | $53M |
| Weighted average shares outstanding | $107.4M | $90.1M | $74M | $72M | $69.4M |
| Weighted average diluted shares outstanding | $107.4M | $90.1M | $74M | $72M | $74M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $981M | $978M | $759M | $1.01B | $499.3M |
| Net receivables | $16M | $25M | $42M | $43M | $746.8M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $1.01B | $1.02B | $831M | $1.07B | $1.26B |
| Property, plant and equipment, net | $40M | $47M | $51M | $135M | $137.4M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $29M | $14M | $107M | $134M | $185M |
| Total non-current assets | $132M | $134M | $264M | $279M | $330.2M |
| Total assets | $1.14B | $1.15B | $1.1B | $1.35B | $1.59B |
| Accounts payable | $42M | $18M | $17M | $20M | $10.3M |
| Short-term debt | $13M | $12M | $11M | $3M | $5.1M |
| Deferred revenue | $35M | $85M | $91M | $97M | $102M |
| Total current liabilities | $231M | $226M | $184M | $193M | $166.1M |
| Long-term debt | $99M | $48M | $0.00 | $117M | $116.9M |
| Deferred revenue, non-current | $43M | $234M | $307M | $355M | $462.2M |
| Total non-current liabilities | $277M | $439M | $449M | $495M | $584.4M |
| Capital lease obligations | $13M | $12M | $11M | $117M | $116.9M |
| Total liabilities | $508M | $665M | $633M | $688M | $750.5M |
| Common stock | $2.12B | $1.62B | $1.31B | $1.21B | $10K |
| Retained earnings | -$-1.49B | -$-1.13B | -$-849M | -$-542M | -$-275.35M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$-7M | -$-1.26M |
| Total equity | $631M | $485M | $462M | $657M | $841.5M |
| Total investments | $788M | $842M | $739M | $937M | $536.4M |
| Total debt | $112M | $60M | $11M | $120M | $122M |
| Net debt | -$-110M | -$-90M | -$-116M | -$-86M | -$-25.93M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-353M | -$-283M | -$-307M | -$-267M | $52.8M |
| Depreciation and amortization | $10M | $10M | $8M | $14M | $3.84M |
| Stock-based compensation | $60M | $76M | $73M | $65M | $55M |
| Change in working capital | -$-194M | $22M | -$-71M | $623M | -$-375.62M |
| Accounts receivable | $9M | $28M | $15M | $704M | -$-17.05M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $14.1M |
| Accounts payable | $24M | $3M | -$-1M | $8M | -$-4.77M |
| Net cash provided by operating activities | -$-482M | -$-170M | -$-306M | $438M | -$-256.17M |
| Investments in property, plant and equipment | -$-2M | -$-6M | -$-24M | -$-6M | -$-26.08M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | -$-22M |
| Net cash used for investing activities | $66M | -$-84M | $194M | -$-413M | -$-3.87M |
| Common stock issued | $439M | $228M | $25M | $23M | $220M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$-10K |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $488M | $277M | $33M | $33M | $237.3M |
| Net change in cash | $72M | $23M | -$-79M | $58.1M | -$-22.7M |
| Cash at end of period | $225M | $153M | $130M | $206M | $150.9M |
| Operating cash flow | -$-482M | -$-170M | -$-306M | $438M | -$-256.17M |
| Capital expenditure | -$-2M | -$-6M | -$-24M | -$-6M | -$-26.08M |
| Free cash flow | -$-484M | -$-176M | -$-330M | $432M | -$-282.25M |
Line items
Line items
Line items
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
- CEO
- Terry J. Rosen
- Employees
- 601
- Beta
- 0.80
Explore
Frequently asked questions
What is the intrinsic value of Arcus Biosciences, Inc. (RCUS)?
Arcus Biosciences, Inc. (RCUS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RCUS undervalued?
RCUS trades at a price of $15.62 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.